Chemo-Immunotherapy in First Line Extensive Stage Small Cell Lung Cancer (ES-SCLC): A Systematic Review and Meta-Analysis

Small cell lung cancer (SCLC) is an aggressive neuroendocrine carcinoma with early metastatic potential. The standard-of-care treatment has not changed in years. Recent studies report improved progression-free survival (PFS) and overall survival (OS) with combined ICI and chemotherapy in ES-SCLC. We...

Full description

Bibliographic Details
Published in:Current Oncology
Main Authors: Arani Sathiyapalan, Michela Febbraro, Gregory R. Pond, Peter M. Ellis
Format: Article
Language:English
Published: MDPI AG 2022-11-01
Subjects:
SCLC
chemotherapy
immunotherapy
extensive stage
chemo-immunotherapy
Online Access:https://www.mdpi.com/1718-7729/29/12/709

Internet

https://www.mdpi.com/1718-7729/29/12/709

Similar Items